We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00205725
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : March 13, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. Antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Hyperglycemia can contribute to long-term cardiovascular disease risk that may already be increased in patients with schizophrenia due to higher rates of smoking, sedentary life style, obesity and under-treated hypertension and dyslipidemia. This project will characterize the effects on glucose control of the two most commonly prescribed newer antipsychotic medications, ziprasidone and olanzapine, in patients with schizophrenia.

Condition or disease Intervention/treatment
Schizophrenia Type 2 Diabetes Mellitus Drug: Ziprasidone, Olanzapine

Detailed Description:

This proposal aims to use a well-characterized procedure, the modified Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT), to characterize the glucoregulatory effects of the two most commonly prescribed atypical antipsychotic medications, ziprasidone and olanzapine, in comparison to the conventional antipsychotic haloperidol. Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia prior to the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation.

Recently, the adverse effect of antipsychotic medications on systemic glucose regulation has received increased attention as investigators noted prominent adverse glucoregulatory effects associated with certain newer antipsychotic medications. Abnormal glucose regulation and new-onset type 2 diabetes have been reported during clozapine and olanzapine treatment. Complicating the study of antipsychotic-induced changes in glucose regulation, increased adiposity can decrease insulin sensitivity, and antipsychotics can increase adiposity and body mass index (BMI). However, abnormal glucose regulation and type 2 diabetes can occur during clozapine treatment in the absence of weight gain, suggesting that changes in glucose regulation can occur independent of drug-induced increases in BMI. Consistent with this, our preliminary studies indicate that important effects of clozapine and olanzapine on glucose regulation are not accounted for by differences in BMI. This proposal will compare the effects of olanzapine, ziprasidone and haloperidol on well-defined measures of glucose regulation.

This proposal specifically hypothesizes that olanzapine treatment will be associated with decreases in insulin sensitivity (SI), without effects on insulin secretion. Treatment-related effects on glucose effectiveness (SG) will be explored.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glucose Regulation During Ziprasidone Treatment
Study Start Date : November 2000
Primary Completion Date : October 2006
Study Completion Date : October 2006

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Effects of olanzapine/ziprasidone/haloperidol on glucose regulation

Secondary Outcome Measures :
  1. Explore treatment-related effects on glucose effectiveness

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients: meets DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder;
  • aged 18 to 60 years;
  • able to give informed consent;
  • no medication changes for 2 weeks prior to and during the period of study;
  • Patients: currently taking an antipsychotic.

Exclusion Criteria:

  • Controls: Axis I psychiatric disorder criteria met except for substance use disorders as below;
  • meets DSM-IV criteria for the diagnoses of substance abuse or dependence within the past six months;
  • involuntary legal status (as per Missouri law);
  • the presence of any serious medical disorder that may (as confirmed by peer-reviewed literature) confound the assessment of symptoms, relevant biologic measures or diagnosis;
  • the following conditions are currently identified:

    • insulin- or non-insulin-dependent diabetes mellitus;
    • any intra-abdominal or intrathoracic surgery or limb amputation within the prior 6 months;
    • any diagnosed cardiac condition causing documented hemodynamic compromise;
    • any diagnosed respiratory condition causing documented or clinically recognized hypoxia;
    • pregnancy or high dose estrogens, fever, narcotic therapy, acute sedative hypnotic withdrawal, corticosteroid or spironolactone therapy, dehydration, epilepsy, endocrine disease, high-dose benzodiazepine therapy (> 25 mg/day of diazepam), or any medical condition known to interfere with glucose utilization;
  • meets DSM-IV criteria for Mental Retardation (mild or worse).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00205725

United States, Missouri
Washington University School of Medicine, Psychiatry Dept.
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: John W. Newcomer, M.D. Washington University School of Medicine and Florida Atlantic University
More Information

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00205725     History of Changes
Other Study ID Numbers: Pfizer IVGTT/941273
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: March 13, 2014
Last Verified: March 2014

Keywords provided by Washington University School of Medicine:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin Antagonists
Dopamine Antagonists
Dopamine Agents